Tango details Phase 3 plans for pancreatic cancer combo, holds $977.5 million
Tango Therapeutics said it will start a front-line Phase 3 trial of vopimetostat plus daraxonrasib in pancreatic cancer in the first half of 2027, following an 82% response rate in earlier-line patients.
SEC filing (3)